Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Camurus AB News

    41,50 € -1,71% -0,72 €
    08:02:22 Uhr Frankfurt aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2ABG7
    ISIN: SE0007692850
    US-Symbol: CAMRF
    Typ: Aktie

    Camurus AB News

    15.07.22 - PLX
    Camurus Q2 Net Income SEK 8 Million
    (PLX AI) – Camurus Q2 revenue SEK 227 million. • Q2 EBIT SEK 7 million
    12.05.22 - PLX
    Camurus Q1 Revenue SEK 220 Million
    (PLX AI) – Camurus Q1 EBIT SEK 5 million.
    16.02.22 - PLX
    Camurus Q4 Revenue SEK 183 Million vs. Estimate SEK 177 Million
    (PLX AI) – Camurus Q4 EBIT SEK -18 million vs. estimate SEK -22 million.
    04.11.21 - PLX
    Camurus Q3 Net Income SEK -6 Million
    (PLX AI) – Camurus Q3 revenue SEK 154 million. • Q3 EBIT SEK -6 million
    13.10.21 - PLX
    Camurus Names Garay Alonso as New CFO
    (PLX AI) – Camurus appoints Jon U. Garay Alonso as Chief Financial Officer from Feb. 1. • He is currently Finance Director, Europe at Baxter International
    16.09.21 - PLX
    Camurus Says FDA Grants Orphan Drug Designation in the US for CAM2029
    (PLX AI) – Camurus says FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease. • Polycystic liver disease (PLD) is a rare, genetic, ...
    15.09.21 - PLX
    Camurus CFO Eva Pinotti-Lindqvist Leaves Company
    (PLX AI) – Camurus Chief Financial Officer (CFO) Eva Pinotti-​Lindqvist will leave the company. • She will continue until a successor is recruited
    15.07.21 - PLX
    Camurus Q2 Net Income SEK -48 Million
    (PLX AI) – Camurus Q2 revenue SEK 138 million vs. estimate SEK 142 million. • Q2 EBIT SEK -60 million vs. estimate SEK -28 million
    26.06.21 - PR Newswire
    Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US
    Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US PR Newswire
    26.06.21 - PR Newswire
    Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US
    Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US New PDUFA action date for Brixadi set for 15 December 2021 PR Newswire
    15.06.21 - PR Newswire
    Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US
    Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US PR Newswire
    15.06.21 - PR Newswire
    Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US
    Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US PR Newswire
    10.05.21 - PR Newswire
    Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence
    Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence PR Newswire
    10.05.21 - PR Newswire
    Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence
    Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence - Randomized, controlled ...
    03.05.21 - PR Newswire
    The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence
    The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence PR Newswire
    03.05.21 - PR Newswire
    The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence
    The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence PR Newswire
    26.03.21 - PR Newswire
    Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence
    Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence PR Newswire
    26.03.21 - PR Newswire
    Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence
    Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence PR Newswire
    18.12.20 - PR Newswire
    Swissmedic approves Buvidal for the treatment of opioid dependence
    Swissmedic approves Buvidal for the treatment of opioid dependence PR Newswire
    18.12.20 - PR Newswire
    Swissmedic approves Buvidal for the treatment of opioid dependence
    Swissmedic approves Buvidal for the treatment of opioid dependence PR Newswire

    Newssuche

    Videos

    newspaper
    08:55 Uhr +5,00%
    Technical Trading: Natural Gas Long Chance
    Erdgas Long Typ: Turbo Open End WKN: VM6KAH Hebel: 2,11 Laufzeit: OpenEnd Einstieg: Market ... Mehr »